At PMC in Westchester, NY, we provide FDA-approved Spravato treatment—a fast-acting esketamine psychedelic therapy designed for individuals with treatment-resistant depression. Administered under direct medical supervision, Spravato offers rapid relief from depressive symptoms, often within minutes, and is especially effective for those struggling with suicidal ideation. Our compassionate care team ensures a safe and supportive environment for every session, helping you regain stability and take the next step toward long-term healing.
The primary benefit of Spravato (esketamine) is its rapid effectiveness, making it a preferred option for psyschedelic therapy treatment. For individuals combatting treatment-resistant depression or thoughts of suicide, its quick response time is a major benefit to this form of treatment.
Esketamine reaches peak concentrations within 20 to 40 minutes, working much faster than traditional antidepressants. It is often recommended for acute major depressive episodes or self-harm ideation.
Your practitioner will determine your appropriate dose, which involves administering nasal puffs from one or more dispensers.
A 56 mg dose requires two devices, while an 84 mg dose uses three. Each puff is taken under supervision, followed by a five-minute rest to ensure absorption.
Spravato (esketamine) can cause sedation, so patients must remain in our Westchester, NY treatment center for at least two hours post-treatment until cleared to leave. A ride home with assistance is required.
Treatment typically starts with twice-weekly doses for the first month. After this period, an evaluation will determine whether adjustments to esketamine therapy are necessary.
Your provider may modify your Spravato therapy based on your response.
Spravato (esketamine) can cause excess sedation (tired feeling), so it’s generally required that patients remain in the treatment center for at least 2 hours until it’s determined that it’s safe for them to leave. You’ll need to have someone help you get home.
There is a risk for abuse and dependence with prolonged esketamine (Spravato) therapy treatment. Your health care provider will evaluate your history and condition to establish whether esketamine is an appropriate option for you.
SPRAVATO has been FDA-approved for certain conditions, so there’s an excellent chance that if you qualify as a candidate, your insurance will cover Spravato.
All policies are different, though, so be sure you discuss your coverage with your provider. Our treatment center in Westchester County, NY can help you to determine whether your coverage will extend to treatment with Spravato.
